Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01501422|
Recruitment Status : Completed
First Posted : December 29, 2011
Last Update Posted : December 28, 2012
- Sex hormone including estrogen have synergistic effect to serotonin activity and decrease activity of monoamine oxidase activity so the norepinephrine is not be metabolized, these substance are important to regulate hemostasis and circadian process of sleep
Estrogen also regulate gamma-aminobutyric acid (GABA) secretion
- GABA substance is in order to initiate sleep and continue sleep
- According to epidemiologic data, problem of sleep was increasing in postmenopause group compare to premenopause group (aged-match)
- This research perform to find out the actual effect of estrogen in improving sleep quality.
|Condition or disease||Intervention/treatment||Phase|
|Insomniac Postmenopausal Women||Drug: Estrogen patch Drug: Placebo||Phase 3|
- 40-60 year-old postmenopausal women with insomnia and mild-moderate vasomotor symptom were screened and included in project
Block of four randomization was use to categorize participants into 2 groups
- Study group (estrogen patch)
- Control group (placebo patch)
Sleep quality was measured before intervention by subjective and objective sleep quality
- Subjective sleep quality (self sleep questionnaire)
- Objective sleep quality (wrist actigraphy and sleep diary):
wrist actigraph sleep test at home for 1 week
Intervention phase : continuous use of weekly patch for 8 weeks
- Estrogen patch in study group
- Placebo patch in control group
Follow up phase
- At 4 weeks of use, investigator will telephone call for follow up the participant's compliance and the side effects during patch use.
- After completed use of 7th patch, sleep quality was measured again, self sleep quality questionnaire and 1 week-wrist actigraphy and sleep diary test
- Then the data will be analysed and open label, in nonhysterectomized postmenopausal women in study group will take the medroxyprogesterone acetate for washing out the endometrium for 2 weeks
- The participants will be counseled, further investigate and proper treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women at Menopause Clinic, King Chulalongkorn Memorial Hospital, Double- Blind, Randomized, Placebo-controlled Trial|
|Study Start Date :||July 2011|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
Use estrogen patch for 8 weeks
Drug: Estrogen patch
50 microgram estrogen patch weekly
Use placebo patch for 8 weeks
Placebo patch for 8 weeks
- Sleep efficiency (SE) [ Time Frame: 8 months ]Sleep efficiency is proportion of sleep in the period potentially filled by sleep-ratio of total sleep time to time in bed.
- Sleep latency (SL) [ Time Frame: 8 months ]Sleep latency is the time period measured from "lights out," or bedtime, to the beginning of sleep.
- Total sleep time (TST) [ Time Frame: 8 months ]TST is amount of actual sleep time in a sleep period.
- Wake time after sleep onset (WASO) [ Time Frame: 8 months ]WASO is the total time of awake occurring between sleep onset and final wake up.
- Number of awakening [ Time Frame: 8 months ]Number of awakening is the number of awakening during onset of sleep and final wake-up.
- Score of two sleep quality assessment questionnaires. [ Time Frame: 8 months ]
- Insomnia severity index is the 7 topic questionnaire for determine the severity of insomnia problem.
- Ebworth severity index is the questionnaire to assess daytime sleepiness.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01501422
|Menopause Clinic, Menopause research unit, King Chulalongkorn Memorial Hospital|
|Pathumwan, Bangkok, Thailand, 10330|
|Principal Investigator:||Pimpika Tansupswatdikul, MD.||Chulalongkorn University|
|Study Chair:||Sukanya Chaikiitisilpa, MD.||Chulalongkorn University|